ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

High-risk rhabdomyosarcoma (RMS) occurring in childhood to young adulthood is associated with a poor prognosis; especially children above the age of 10 with advanced stage alveolar RMS still succumb to the disease within a median of 2 years. The advent of chimeric antigen receptor (CAR)-engineered T...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michael Merker, Juliane Wagner, Hermann Kreyenberg, Catrin Heim, Laura M. Moser, Winfried S. Wels, Halvard Bonig, Zoltán Ivics, Evelyn Ullrich, Thomas Klingebiel, Peter Bader, Eva Rettinger
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2020-10-01
Edice:	Frontiers in Immunology
Témata:	cellular therapy cytokine-induced killer cells chimeric antigen receptor rhabdomyosarcoma ERBB2 (HER2/neu)
On-line přístup:	https://www.frontiersin.org/article/10.3389/fimmu.2020.581468/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!